The Soluble Fiber α-Cyclodextrin Does Not Increase the Fecal Losses of Dietary Fat in Adults—A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial

Abstract

α-CD supplementation did not increase loss of dietary lipid in stool or total fecal fat compared with placebo in healthy adults. Greater stool loss and lesser appearance in plasma TGs of tripalmitin-derived [14C] compared with triolein-derived [3H] TGs imply different metabolic handling of these 2 dietary fat tracers. This trial was registered at www.clinicaltrials.gov as NCT03002168.

The effect of alpha-cyclodextrin on postprandial glucose excursions, a systematic meta analysis Alpha-cyclodextrin and Blood Glucose

“…The comparisons based on the four subsequent studies (Gentilcore 2011;Sugahara 2016;Bär 2020;Binou 2022a;b) , excluding the two studies serving high-fat meals (Jarosz 2013;Lytle 2018) , are consistent with the doseresponse relationship initially observed (Buckley 2006) :…”

“…The comparisons based on the four subsequent studies [4, 5, 21-23], excluding the two studies serving high-fat meals [11, 17], are consistent with a dose-response relationship [14]:…”

“…One of the most striking observations are the glucose curves in the two studies with the highest fat and protein content [11, 17], where blood glucose levels increased by only 10% under control conditions, compared to ∼50% in studies serving a high-carbohydrate diet. (Figure 1D has been rescaled from [24, Figure 2] to reflect that aspect.)…”

“…To facilitate comparisons, the figures given below have been scaled and cropped, and elements have been resized or removed (like indicators of significance of comparisons not being considered), while some information have been added from the text. No information was removed, except values beyond 180 min (2 h) in two studies (Gentilcore 2011; Lytle 2018) .…”

“…This systematic review and included clinical studies of dietary interventions that (1) enrolled, regardless of their age and background, who were generally healthy, (2) were randomized or non- Three additional publications were identified. One had glucose profiles only as a secondary outcome [11], the other two were published only after the FDA had made its decision; one is included [22,23], another study (a combination treatment with 5 g αCD per meal, 45% calories from carbohydrates) was terminated because of poor compliance during COVID [13].…”